近5亿融资！肺部神经调控系统完成A轮

Core Viewpoint - Spiro Medical has completed a $67 million (approximately 470 million RMB) Series A funding round to support the development of its Pulmonary Neuromodulation (PNM) system, aimed at treating respiratory diseases such as asthma [2][10]. Group 1: Funding and Development - The funding will be utilized for the ongoing research and clinical studies necessary to meet regulatory requirements in the U.S. [2][10]. - Post-funding, the company's primary focus will be on engineering improvements and clinical validation of the PNM system [2][10]. Group 2: Technology Overview - Neuromodulation technology aims to adjust nerve signal transmission through implanted or non-implanted devices to improve specific disease-related nerve functions [4][6]. - The PNM system is designed to directly influence nerve pathways related to respiratory function, potentially reducing reliance on conventional medications for asthma [6][8]. Group 3: Clinical Progress - Spiro Medical has completed an early exploratory clinical study, which indicated that the PNM technology could control asthma symptoms without medication, improving quality of life for some participants [10]. - The company holds three authorized patents, establishing a foundational intellectual property base for future development [10]. Group 4: Company Profile - Spiro Medical, based in Irvine, California, focuses on developing the PNM system for treating respiratory diseases, particularly asthma [12]. - The PNM system integrates implanted medical devices, neuromodulation technology, and digital tools, aiming for a minimally invasive approach to affect airway reactivity [12]. Group 5: Future Directions - The company plans to continue product development and clinical validation centered on asthma, while also exploring applications for chronic cough and chronic obstructive pulmonary disease (COPD) [12][13]. - The completion of the funding round is seen as a critical support for the exploration of this emerging technology, although its long-term clinical value and applicable patient demographics require further data [13].